Startseite › Speiseröhrenkrebs › Texas › Houston
Klinische Studien zu Speiseröhrenkrebs in Houston, TX
36 Studien zu Speiseröhrenkrebs suchen Teilnehmer an Standorten in und um Houston (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Texas MD Anderson Cancer Center, Houston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Teilnehmer gesuchtPhase 2
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- UT MD Anderson Cancer Center, Houston
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Texas MD Anderson Cancer Center, Houston
- The University of Texas, MD Anderson Cancer Center - West Houston, Houston
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Teilnehmer gesuchtPhase 2
- MD Anderson Cancer Center (Data Collection Only), Houston
Pan-tumor MRD Study
Teilnehmer gesuchtBeobachtungsstudie
- Onocology Consultants P.A. (Oncology Consultants [OC Houston]), Houston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Teilnehmer gesuchtPhase 1
- MD Anderson Cancer Center, Houston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Teilnehmer gesuchtPhase 1
- Baylor College of Medicine, Houston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Teilnehmer gesuchtPhase 1/2
- MD Anderson, Houston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Teilnehmer gesuchtPhase 1
- Oncology Consultants, P.A., Houston
- University of Texas M.D. Anderson Cancer Center, Houston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Teilnehmer gesuchtPhase 1
- Oncology Consultants, Houston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Teilnehmer gesuchtPhase 3
- Research Site, Houston
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Teilnehmer gesuchtPhase 1/2
- University of Texas MD Anderson Cancer Center ( Site 8920), Houston
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
Teilnehmer gesuchtPhase 1/2
- University of Texas MD Anderson Cancer Center ( Site 6920), Houston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- The University of Texas, MD Anderson Cancer Center, Houston
IDOV-Immune for Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- MD Anderson Cancer Center, Houston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Oncology Consultants, Houston
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Teilnehmer gesuchtPhase 2
- MD Anderson Cancer Center, Houston
Lead-212 PSV359 Therapy for Patients With Solid Tumors
Teilnehmer gesuchtPhase 1/2
- MD Anderson Cancer Center, Houston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- Oncology Consultants, PA, Houston
- Oncology Consultants, PA., Houston
- The University of Texas M.D. Anderson Cancer Center, Houston
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Teilnehmer gesuchtPhase 1
- The University of Texas MD Anderson Cancer Center /ID# 270059, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Teilnehmer gesuchtBeobachtungsstudie
- M D Anderson Cancer Center, Houston
Serologic Response to Pneumococcal Vaccination Among Esophageal Cancer Patients With High Grade Lymphopenia After Chemoradiation
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- MD Anderson Cancer Center, Houston
18F-AraG PET/CT as a Non-Invasive Imaging Biomarker for Chemoradiation Treatment Response in Esophageal Cancer
Teilnehmer gesuchtPhase 1
- MD Anderson Cancer Center, Houston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- MD Anderson Cancer Center, Houston
Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
Teilnehmer gesuchtGesunde Freiwillige willkommen
- M D Anderson Cancer Center, Houston
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
Teilnehmer gesuchtPhase 2
- M D Anderson Cancer Center, Houston
Novel Bipolar Radiofrequency Ablation Knife in Esophageal Lesions
Teilnehmer gesuchtBeobachtungsstudie
- Baylor College of Medicine, Houston
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Teilnehmer gesuchtBeobachtungsstudie
- Md Anderson Cancer Center, Houston
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Teilnehmer gesuchtPhase 1
- Baylor St. Luke's Medical Center, Houston
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1
- Oncology Consultants, Houston
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- The University of Texas MD Anderson Cancer Center, Houston
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Teilnehmer gesuchtPhase 1/2
- The University of Texas MD Anderson Cancer Center (site 127), Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Houston
Distribution of Lymph Node Metastases in Esophageal Carcinoma
Teilnehmer gesuchtBeobachtungsstudie
- MD Anderson Cancer Center, Houston
Speiseröhrenkrebs-Studien in anderen Städten
- Boston, MA23 Studien
- New York City, NY22 Studien
- Nashville, TN19 Studien
- St. Louis, MO17 Studien
- Pittsburgh, PA15 Studien
- Los Angeles, CA15 Studien
- Baldwin Park, CA14 Studien
- Grand Rapids, MI14 Studien
- Philadelphia, PA13 Studien
- San Antonio, TX12 Studien
- Rochester, MN11 Studien
- Arlington, VA11 Studien
Weitere Studien in Houston
- Nichtkleinzelliges Lungenkarzinom145 Studien
- Brustkrebs126 Studien
- Krebs (alle Arten)121 Studien
- Metastasierender Krebs104 Studien
- Kolorektales Karzinom102 Studien
- Eierstockkrebs89 Studien
- Akute myeloische Leukämie85 Studien
- Lungenkrebs78 Studien
- Prostatakrebs76 Studien
- Endometriumkarzinom68 Studien
- Bauchspeicheldrüsenkrebs61 Studien
- Melanom59 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.